Sign In
Buy TEVA
$32.83
-0.250 (-0.756%)
At Close: Jun 03, 2026
Teva Pharma Surges On Its Big Sales Beat, Austedo Guidance Hike
08:46am, Wednesday, 05'th Nov 2025
Teva stock jumped early Wednesday on better-than-expected third-quarter metrics and a sales guidance hike for Austedo.
Teva Pharm third-quarter profit tops estimates as branded drugs gain
07:44am, Wednesday, 05'th Nov 2025
Teva Pharmaceutical Industries reported on Wednesday a higher-than-expected rise in third-quarter profit, helped by strong sales of its trio branded drugs to treat migraines, Huntington's disease and
Teva's Innovative Portfolio Drives 11th Consecutive Quarter of Growth in Q3 2025; Increases 2025 Outlook for Austedo® and Non-GAAP EPS
07:00am, Wednesday, 05'th Nov 2025
For an accessible version of this Press Release, please visit www.tevapharm.com Teva reports revenues of $4.5 billion in the third quarter of 2025, an increase of 3% year-over-year (YoY) in U.S. dolla
Seeking Clues to Teva Pharmaceutical Industries (TEVA) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics
10:15am, Tuesday, 04'th Nov 2025
Evaluate the expected performance of Teva Pharmaceutical Industries (TEVA) for the quarter ended September 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining
Here's Why This Israeli Investment Giant Is Betting $834 Million on Teva Stock
10:55am, Monday, 03'rd Nov 2025
Israel-based Phoenix Financial acquired more than 3.5 million additional shares of Teva Pharmaceuticals for an estimated $62.1 million in the third quarter. Post-transaction, the fund reported holding
Teva to Present at UBS Global Healthcare Conference and Jefferies London Healthcare Conference in November
04:30pm, Friday, 31'st Oct 2025
TEL AVIV, Israel, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at two upco
Blood pressure medicine recalled over high levels of cancer-causing chemical
11:45am, Thursday, 30'th Oct 2025
More than half a million bottles of Prazosin Hydrochloride have been recalled over high levels of a chemical compound that could cause cancer, the FDA said.
Teva Pharmaceutical Industries Ltd. $TEVA Shares Sold by Ethic Inc.
04:04am, Thursday, 30'th Oct 2025
Ethic Inc. reduced its stake in Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) by 7.0% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Com
Harel Bets Big on Teva Pharmaceutical by Purchasing 4.3 Million Shares
01:01pm, Wednesday, 29'th Oct 2025
Added 4,306,363 Teva shares, an estimated $75.64 million trade based on the average quarterly price for Q3 2025 Transaction represents a 0.68% increase in reportable U.S. equity assets under managemen
Yousif Capital Management LLC Purchases 2,830 Shares of Teva Pharmaceutical Industries Ltd. $TEVA
05:18am, Wednesday, 22'nd Oct 2025
Yousif Capital Management LLC increased its position in shares of Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) by 5.1% in the undefined quarter, according to the company in its most recent 13F fil
Analyzing Amphastar Pharmaceuticals (NASDAQ:AMPH) and Teva Pharmaceutical Industries (NYSE:TEVA)
01:48am, Wednesday, 22'nd Oct 2025
Amphastar Pharmaceuticals (NASDAQ: AMPH - Get Free Report) and Teva Pharmaceutical Industries (NYSE: TEVA - Get Free Report) are both medical companies, but which is the superior investment? We will c
All You Need to Know About Teva Pharmaceutical Industries (TEVA) Rating Upgrade to Buy
01:01pm, Tuesday, 21'st Oct 2025
Teva Pharmaceutical Industries (TEVA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term
Does Teva Pharmaceutical Industries (TEVA) Have the Potential to Rally 28.12% as Wall Street Analysts Expect?
10:56am, Tuesday, 21'st Oct 2025
The consensus price target hints at a 28.1% upside potential for Teva Pharmaceutical Industries (TEVA). While empirical research shows that this sought-after metric is hardly effective, an upward tren
Should Value Investors Buy Teva Pharmaceutical Industries (TEVA) Stock?
10:41am, Tuesday, 21'st Oct 2025
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Teva and Prestige Biopharma Enter License Agreement for Tuznue® Commercialization in Europe
04:30pm, Monday, 20'th Oct 2025
Teva and Prestige announce a license and supply agreement for the commercialization of Prestige's Tuznue ® , a biosimilar to Herceptin ® (trastuzumab) Tuznue ® received European Commission (EC) mar
